Q-linea AB's revenue for the
three
months ended in Jun. 2025 was kr1.08 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2025 was kr5.49 Mil.
Q-linea AB's Revenue per Share for the
three
months ended in Jun. 2025 was kr0.21.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was kr2.72.
Warning Sign:
Q-linea AB revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Q-linea AB was -85.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -60.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, Q-linea AB's highest 3-Year average Revenue per Share Growth Rate was 132.90% per year. The lowest was -60.60% per year. And the median was 78.30% per year.
Q-linea AB Revenue Historical Data
The historical data trend for Q-linea AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Q-linea AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB's Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Revenue distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINEs) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Q-linea AB Revenue Related Terms
Thank you for viewing the detailed overview of Q-linea AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:QLINES has been successfully added to your 